Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings available to its subscribers [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [4]

PHILADELPHIA, July 16, 2025 /PRNewswire/ -- Berger Montague announces a securities fraud investigation into Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) concerning potential violations of the Securities Exchange Act of 1934. The inquiry focuses on whether investors were misled about the Company's regulatory compliance and business operations.Following Novo Nordisk's termination of its collaboration with Hims & Hers on June 23, 2025, the Company's stock dropped more than 34%. A class ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, to seek lead plaintiff status [1]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding the safety of its products [2]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices that jeopardized patient safety, leading to a stock price decline of over 34% [3]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Hims & Hers securities during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [4]. Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=156722&from=3 CLASS PERIOD: A ...

Core Viewpoint - The sudden termination of the partnership between Hims & Hers Health and Novo Nordisk has led to increased legal troubles for the telehealth company, including multiple investor lawsuits alleging misleading information regarding financial status and future performance guidance [1][2]. Group 1: Partnership and Legal Issues - Hims & Hers Health's collaboration with Novo Nordisk lasted only two months before being abruptly ended due to legal and marketing disputes, resulting in a significant drop in Hims & Hers' stock price by approximately 35% in a single day [1][2]. - Following the partnership's termination, investors filed several securities class action lawsuits against Hims & Hers in federal court, accusing the company of insufficient disclosure regarding the importance of the partnership and compliance risks [2]. Group 2: Financial Impact and Market Concerns - The termination of the partnership has raised concerns about Hims & Hers' financial performance, particularly regarding legal and brand costs, as well as uncertainties surrounding the supply of Novo Nordisk's GLP-1 products [2]. - If the lawsuits result in liability and restrictions on the sale of compounded drugs, along with a continued decline in gross margins, this could exert substantial pressure on the company's mid-term profitability [2][3]. - The active ingredient semaglutide (Wegovy) was recently removed from the FDA's shortage list, leading to Novo Nordisk's demand for Hims & Hers to cease sales of compounded versions, which has sparked further disputes [3]. - The potential inability to sell compounded Wegovy, combined with supply limitations from the broken partnership, may slow growth in the high-margin weight loss sector, with gross margins projected to decline from 79% in 2024 to 73% in Q1 2025 [3].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations and Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

Core Insights - The stock of Hims & Hers Health (NYSE: HIMS) was initially discovered when trading around $20, and a 50% return was realized upon selling, although a subsequent bullish run was missed [1]. Company Profile - Hims & Hers Health operates in the healthcare sector, focusing on telehealth services and wellness products, which have gained traction in recent years due to increased consumer demand for accessible healthcare solutions [1]. Analyst Background - The analyst has a strong background in finance and risk analysis, holding an MSc in Applied Risk Management and having worked in various roles across leading firms, indicating a solid foundation for evaluating investment opportunities [1]. Investment Strategy - The approach to investing emphasizes data-driven analysis and long-term value creation, with a focus on risk management and financial modeling, which are critical for assessing the potential of stocks like Hims & Hers Health [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and unsafe practices related to the promotion of drugs, particularly in connection with a terminated partnership with Novo Nordisk [2][4][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Hims to contact them for discussing legal options [1]. - The firm is investigating claims against Hims and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Hims engaged in deceptive promotion and selling of illegitimate drugs, risking patient safety and misleading investors about the company's operations and prospects [4]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and deceptive marketing practices [5]. - Following the announcement, Hims' stock price fell by $22.24, or 34.6%, closing at $41.98 per share, significantly impacting investors [5]. Group 3: Class Action and Lead Plaintiff Information - The court-appointed lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Whistleblower Encouragement - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Hims' conduct, including whistleblowers and former employees, to contact the firm [7].

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;" (2) as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleadi ...

Group 1: Hong Kong Stock Market Highlights - Yunfeng Financial (00376) surged over 21% as the company plans to strategically invest in digital currency and AI sectors [1] - China Merchants Securities (06099) opened nearly 15% higher and is currently up over 4% after receiving approval for a virtual asset license [1] - GDS Holdings (09698) rose over 7% as its Southern GDS data center REIT concluded public investor fundraising ahead of schedule [1] - Hillstone Technology (01478) increased nearly 6% with positive earnings expectations, and Citigroup anticipates a favorable market reaction [1] - Sunny Optical Technology (02382) briefly rose over 3% and is currently up over 1% as its lithography equipment successfully entered Shanghai, indicating a shift to mass production [1] - Kintor Pharmaceutical (02171) saw an early gain of over 3% after achieving positive results in the European patent opposition process [1] - Bilibili (09626) rose over 5% as HSBC expressed optimism about its gaming and advertising business, with new games planned for 2025 [1] - Solar stocks experienced a decline, with institutions citing electricity prices affecting the stable profitability of new energy projects [1] Group 2: U.S. Stock Market Highlights - The U.S. nuclear sector saw gains, with NuScale Power (SMR.US) up 12.38% and Oklo Inc (OKLO.US) up 11.29%, following comments from the U.S. Energy Secretary about a nuclear revival [3] - Autodesk (ADSK.US) rebounded 5.05% after a period of decline, expressing confidence in its cloud and AI business strategies [3] - Sonnet BioTherapeutics (SONN.US) surged 86.46% due to a merger announcement, forming a cryptocurrency financial company valued at $888 million [3] - Quantum stocks rose, with D-Wave Quantum (QBTS.US) up 6.89% and Quantum Computing (QUBT.US) up 8.66% [3] - Hims & Hers Health (HIMS.US) increased 8.64% as it plans to enter the Canadian market with a generic drug following the expiration of a patent [4] - Rocket Lab (RKLB.US) rose 10.71% after Citigroup raised its target price, noting a significant increase in global space technology investments [4] - Nvidia-related stocks mostly strengthened as Jensen Huang made his third visit to China this year [5] - Cryptocurrency stocks collectively rose, with Bitcoin surpassing $120,000, driven by upcoming legislative reviews in the U.S. [5] - Tesla (TSLA.US) gained 1.08% amid investor speculation regarding a stake in xAI [5] - Netflix (NFLX.US) rose 1.35% ahead of its upcoming earnings report, with analysts projecting significant revenue growth [6]